Marilyn K. Boardman

1.3k total citations · 1 hit paper
12 papers, 1.1k citations indexed

About

Marilyn K. Boardman is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Marilyn K. Boardman has authored 12 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Molecular Biology and 2 papers in Surgery. Recurrent topics in Marilyn K. Boardman's work include Diabetes Treatment and Management (10 papers), Diabetes Management and Research (7 papers) and Metabolism, Diabetes, and Cancer (6 papers). Marilyn K. Boardman is often cited by papers focused on Diabetes Treatment and Management (10 papers), Diabetes Management and Research (7 papers) and Metabolism, Diabetes, and Cancer (6 papers). Marilyn K. Boardman collaborates with scholars based in United States, Japan and Taiwan. Marilyn K. Boardman's co-authors include Byron J. Hoogwerf, Wayne H.-H. Sheu, Sylvia Shenouda, Cory R. Heilmann, Michael A. Nauck, Mark Fineman, Guntram Schernthaner, Aijun Gao, John B. Buse and Thomas Först and has published in prestigious journals such as The Lancet, Diabetes Care and The Lancet Diabetes & Endocrinology.

In The Last Decade

Marilyn K. Boardman

12 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

2012 460 citations John B. Buse, Michael A. Nauck et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marilyn K. Boardman United States	10	1.0k	470	358	275	84	12	1.1k
Julie Derving Karsbøl Denmark	9	1.1k 1.1×	737 1.6×	277 0.8×	290 1.1×	94 1.1×	15	1.2k
Ken Wilhelm United States	6	874 0.9×	371 0.8×	336 0.9×	236 0.9×	75 0.9×	7	952
P. Miossec France	12	991 1.0×	455 1.0×	376 1.1×	204 0.7×	83 1.0×	22	1.1k
Shizuka Kaneko Japan	11	847 0.8×	400 0.9×	291 0.8×	287 1.0×	188 2.2×	23	1.0k
Christopher Sorli United States	13	832 0.8×	421 0.9×	443 1.2×	286 1.0×	225 2.7×	28	1.2k
Ted Okerson United States	11	845 0.8×	364 0.8×	479 1.3×	255 0.9×	89 1.1×	21	1.0k
Mario Widel United States	7	764 0.7×	430 0.9×	281 0.8×	139 0.5×	68 0.8×	11	922
Charles Atisso United States	7	812 0.8×	465 1.0×	253 0.7×	244 0.9×	84 1.0×	18	864
Jorma Strand Denmark	4	759 0.7×	456 1.0×	281 0.8×	196 0.7×	66 0.8×	5	836
Christof Kazda United States	13	836 0.8×	290 0.6×	411 1.1×	234 0.9×	175 2.1×	30	1.0k

Countries citing papers authored by Marilyn K. Boardman

Since Specialization

Citations

This map shows the geographic impact of Marilyn K. Boardman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marilyn K. Boardman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marilyn K. Boardman more than expected).

Fields of papers citing papers by Marilyn K. Boardman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marilyn K. Boardman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marilyn K. Boardman. The network helps show where Marilyn K. Boardman may publish in the future.

Co-authorship network of co-authors of Marilyn K. Boardman

This figure shows the co-authorship network connecting the top 25 collaborators of Marilyn K. Boardman. A scholar is included among the top collaborators of Marilyn K. Boardman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marilyn K. Boardman. Marilyn K. Boardman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Perreault, Leigh, Marilyn K. Boardman, & Jonathan Pak. (2019). The Association Between Type 2 Diabetes and Cardiovascular Disease: The “For Your SweetHeart™” Survey. Advances in Therapy. 36(3). 746–755. 9 indexed citations

Simeone, Jason C., Jay Bae, Byron J. Hoogwerf, et al.. (2017). Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clinical Epidemiology. Volume 9. 679–688. 27 indexed citations

Diamant, Michaëla, Luc Van Gaal, Bruno Guerci, et al.. (2014). Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. The Lancet Diabetes & Endocrinology. 2(6). 464–473. 134 indexed citations

Trautmann, Michael, Luc F. Van Gaal, Bruno Guerci, et al.. (2013). 1.3 Exenatide Once Weekly: Sustained Glycemic and Weight Control Through 3 Years Compared with Insulin Glargine (67-OR). 11(3). 76–76. 2 indexed citations

Onishi, Yukiko, Hiroyuki Koshiyama, Takeshi Imaoka, et al.. (2012). Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 4(2). 182–189. 11 indexed citations

Norwood, Paul, Joanne Liutkus, Harry Haber, et al.. (2012). Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years. Clinical Therapeutics. 34(10). 2082–2090. 22 indexed citations

Onishi, Yukiko, Chul Woo Ahn, Pankaj Kumar Agarwal, et al.. (2012). Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 4(1). 53–61. 67 indexed citations

Buse, John B., Michael A. Nauck, Thomas Först, et al.. (2012). Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. The Lancet. 381(9861). 117–124. 460 indexed citations breakdown →

Russell‐Jones, David, Robert Cuddihy, M Hanefeld, et al.. (2011). Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4). Diabetes Care. 35(2). 252–258. 296 indexed citations

10.

Kadowaki, Takashi, Mitsuyoshi Namba, Takeshi Imaoka, et al.. (2010). Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. Journal of Diabetes Investigation. 2(3). 210–217. 48 indexed citations

11.

Lorenzi, Gayle M., et al.. (2010). Application of Adult-Learning Principles to Patient Instructions: A Usability Study for an Exenatide Once-Weekly Injection Device. Clinical Diabetes. 28(4). 157–162. 16 indexed citations

12.

Boardman, Marilyn K., Katie Mellor, & Bridget A. Neville. (1993). Treating a patient with a heavily exuding malodorous fungating ulcer. Journal of Wound Care. 2(2). 74–76. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact